Prothena CORP Public LTD CO Form 4 insider transactions

Prothena Corp Public Ltd Co's Chief Scientific Officer, Wagner M. Zago, acquired 85,000 ordinary shares at a price of $0, indicating a grant or award.

Prothena's Chief Accounting Officer, Karin L. Walker, acquired 25,000 ordinary shares at a price of $0, effective July 28, 2025, under a pre-arranged Rule 10b5-1 plan.

Prothena Corp Public Ltd Co's Chief Development Officer, Chad J. Swanson, is set to acquire 85,000 ordinary shares at a price of $0 per share on July 28, 2025, as part of a pre-planned transaction.

Prothena's Chief Operating Officer, Brandon S. Smith, acquired 130,000 ordinary shares of the company at no cost, increasing his direct beneficial ownership.

Prothena's Chief Strategy Officer and CFO, Tran Nguyen, acquired 95,000 ordinary shares at a price of $0, increasing beneficial ownership to 97,205 shares.

Prothena Biosciences' Chief Legal Officer, Michael J. Malecek, was granted 80,000 ordinary shares at a price of $0, increasing his direct beneficial ownership.

Prothena Corp Public Ltd Co's President and CEO, Gene G. Kinney, is set to acquire 140,000 ordinary shares at a price of $0 per share on July 28, 2025, increasing his direct beneficial ownership to 152,793 shares.

Director Daniel G. Welch reports acquisition of stock options in Prothena Corp Public Ltd Co.

Director Dennis J. Selkoe reports the acquisition of stock options for 20,183 ordinary shares of Prothena Corp Public Ltd Co.

Director Helen Susan Kim acquired stock options for 20,183 ordinary shares in Prothena Corp Public LTD CO on May 14, 2025.

Director Lars Ekman reports acquisition of stock options in Prothena Corp Public Ltd Co.

Director William H. Dunn Jr. reports the acquisition of stock options for 20,183 ordinary shares of Prothena Corp Public Ltd Co.

Director Shane Cooke acquired 20,183 stock options in Prothena Corp Public Ltd Co on May 14, 2025, exercisable at $6.885, vesting on the earlier of the first anniversary of the grant date or the 2026 annual general meeting.

Richard T. Collier, a director of Prothena Corp Public LTD CO, acquired 20,183 stock options on May 14, 2025, exercisable for ordinary shares.

Director Paula K. Cobb reports acquisition of 20,183 stock options in Prothena Corp Public LTD CO on May 14, 2025.

EcoR1 Capital, a 10% owner of Prothena Corp Public Ltd Co, reports selling a significant number of ordinary shares over three days in May 2025.

William Scully, a director and 10% owner of Prothena Corp Public Ltd Co, reports multiple transactions involving ordinary shares between December 2024 and January 2025.

Wagner M. Zago, Chief Scientific Officer of Prothena Corp Public Ltd Co, reports the acquisition of stock options for 107,500 ordinary shares.

Karin L. Walker, Chief Accounting Officer of Prothena Corp Public Ltd Co, reports the acquisition of 70,000 stock options exercisable at $14.95, vesting over four years.

Chad J. Swanson, Chief Development Officer of Prothena Corp Public Ltd Co, acquired stock options for 107,500 ordinary shares on March 5, 2025.

Brandon S. Smith, Chief Operating Officer of Prothena Corp Public Ltd Co, reports the acquisition of stock options.

Tran Nguyen, Chief Strategy Officer and CFO of Prothena Corp Public LTD CO, reports the acquisition of stock options.

Michael J. Malecek, Chief Legal Officer of Prothena Corp Public Ltd Co, reports the acquisition of stock options.

Gene G. Kinney, President and CEO of Prothena Corp Public LTD CO, acquired 375,000 stock options on March 5, 2025, according to a Form 4 filing with the SEC.

Carol D. Karp, Chief Regulatory Officer of Prothena Corp Public Ltd Co, reports the acquisition of stock options for 107,500 ordinary shares.

David A. Ford, Chief People Officer of Prothena Corp Public LTD CO, reports the acquisition of stock options for 107,500 ordinary shares.

Tran Nguyen, Chief Strategy Officer and CFO of Prothena Corp Public LTD CO, reports the transfer of 995 ordinary shares to a former spouse as part of a divorce settlement on April 8, 2020.

Chad J. Swanson, Chief Development Officer of Prothena Corp Public Ltd Co, reports the acquisition of stock options.

Director Daniel G. Welch acquired 15,000 stock options in Prothena Corp Public Ltd Co on May 15, 2024, at an exercise price of $22.39.

Director Dennis J. Selkoe of Prothena Corp acquired 15,000 stock options at an exercise price of $22.39 on May 15, 2024.